Abstract
Programmed cell death (apoptosis) is a key tumor suppressor mechanism. Consequently, most if not all cancers develop mechanisms to abolish or circumvent this genetic program. Besides enabling malignant transformation and tumor progression, defects in apoptosis can result in resistance to cytotoxic cancer therapies. Much progress has been made in the delineation of the molecular pathways leading to apoptosis. This allows the identification of target molecules and lead compounds to develop novel therapies, which make use of this intrinsic death program for the treatment of cancer. Here, we review the current understanding of apoptotic signal transduction pathways, and strategies of their therapeutic modulation in relation to lymphoma and other cancers.
Keywords: BH3-only proteins, p53 Gene Transfer, pro-apoptotic genes, TNF receptor superfamily, Mouse-double-minute-2 (MDM-2)
Current Drug Targets
Title: Therapeutic Targeting of Apoptotic Pathways in Cancer
Volume: 7 Issue: 10
Author(s): Johannes Meiler and Martin Schuler
Affiliation:
Keywords: BH3-only proteins, p53 Gene Transfer, pro-apoptotic genes, TNF receptor superfamily, Mouse-double-minute-2 (MDM-2)
Abstract: Programmed cell death (apoptosis) is a key tumor suppressor mechanism. Consequently, most if not all cancers develop mechanisms to abolish or circumvent this genetic program. Besides enabling malignant transformation and tumor progression, defects in apoptosis can result in resistance to cytotoxic cancer therapies. Much progress has been made in the delineation of the molecular pathways leading to apoptosis. This allows the identification of target molecules and lead compounds to develop novel therapies, which make use of this intrinsic death program for the treatment of cancer. Here, we review the current understanding of apoptotic signal transduction pathways, and strategies of their therapeutic modulation in relation to lymphoma and other cancers.
Export Options
About this article
Cite this article as:
Meiler Johannes and Schuler Martin, Therapeutic Targeting of Apoptotic Pathways in Cancer, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559175
DOI https://dx.doi.org/10.2174/138945006778559175 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Versatile and Valuable Utilization of Amidohydrolase L-glutaminase in Pharma and Food industries: A Review
Current Drug Metabolism Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Blocking the Path to Death: Anti-Apoptotic Molecules in Ischemia /Reperfusion Injury of the Liver
Current Pharmaceutical Design Enhancement Antimicrobial Activity of Clarithromycin by Amine Functionalized Mesoporous Silica Nanoparticles as Drug Delivery System
Letters in Drug Design & Discovery To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis
Current Immunology Reviews (Discontinued) N-Hydroxyguanidines as Substrates of Nitric Oxide Synthases
Current Topics in Medicinal Chemistry Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Toxicity of Biodegradable Nanoscale Preparations
Current Drug Metabolism Lessons Learned from the Irinotecan Metabolic Pathway
Current Medicinal Chemistry Current Status and Future of Target-Based Therapeutics
Current Cancer Drug Targets Platelet Protein Synthesis and Translational Control
Current Proteomics Characterization of a Saccharide-Binding Protein from Talisia esculenta Seeds with Trypsin Inhibitory Activity
Protein & Peptide Letters Inclusion Complexes of Halide Anions with Macrocyclic Receptors
Current Organic Chemistry Current and Emerging Therapies in Primary Myelofibrosis
Cardiovascular & Hematological Disorders-Drug Targets Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry ET-18-OCH3 (Edelfosine): A Selective Antitumour Lipid Targeting Apoptosis Through Intracellular Activation of Fas / CD95 Death Receptor
Current Medicinal Chemistry Development and Validation of a Rapid and Sensitive Assay for Simultaneous Quantification of Lenalidomide and Dexamethasone in Human Plasma by Liquid Chromatography Coupled to Tandem Mass-Spectrometry
Current Pharmaceutical Analysis Can Dietary Antioxidants Reduce the Incidence of Brain Tumors?
Current Drug Metabolism Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
Current Cancer Drug Targets